Activation of Wnt signaling through b-catenin mutations contributes to the development of hepatocellular carcinoma (HCC) and hepatoblastoma (HB). To explore the contribution of additional Wnt pathway molecules to hepatocarcinogenesis, we examined b-catenin, AXIN1 and AXIN2 mutations in 73 HCCs and 27 HBs. b-catenin mutations were detected in 19.2% (14 out of 73) HCCs and 70.4% (19 out of 27) HBs. b-catenin mutations in HCCs were primarily point mutations, whereas more than half of the HBs had deletions. AXIN1 mutations occurred in seven (9.6%) HCCs and two (7.4%) HBs. The AXIN1 mutations included seven missense mutations, a 1 bp deletion, and a 12 bp insertion. The predominance of missense mutations found in the AXIN1 gene is different from the small deletions or nonsense mutations described previously. Loss of heterozygosity at the AXIN1 locus was present in four of five informative HCCs with AXIN1 mutations, suggesting a tumor suppressor function of this gene. AXIN2 mutations were found in two (2.7%) HCCs but not in HBs. Two HCCs had both AXIN1 and b-catenin mutations, and one HCC had both AXIN2 and b-catenin mutations. About half the HCCs with AXIN1 or AXIN2 mutations showed b-catenin accumulation in the nucleus, cytoplasm or membrane. Overall, these data indicate that besides the approximately 20% of HCCs and 80% of HBs with b-catenin mutations contributing to hepatocarcinogenesis, AXIN1 and AXIN2 mutations appear to be important in an additional 10% of HCCs and HBs.
Introduction
Hepatocellular carcinoma (HCC) and hepatoblastoma (HB) are primary liver cancers that occur predominantly in adults and children, respectively. HCC is the major histologic type of malignant primary liver neoplasm. It is the fifth most common cancer and the third most common cause of death from cancer worldwide (Ferlay et al., 2001) . The major risk factors for HCC are chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, prolonged dietary aflatoxin exposure, alcoholic cirrhosis, and cirrhosis due to other causes such as hereditary hemochromatosis (Schafer and Sorrell, 1999) . HBs comprise 1 -2% of all malignant neoplasms of childhood, most often occurring in children under 3 years of age. HBs are thought to be derived from undifferentiated hepatocytes (Raney, 1997) .
The pathogenesis of primary liver tumors has been extensively explored. The hepatocellular injury and inflammation that characterize chronic hepatitis B and C infection presumably result in cycles of liver cell death and regeneration that lead to accelerated hepatocellular senescence, telomeric crisis, and associated chromosomal and genomic instability that contribute to carcinogenesis. Molecular pathways implicated in liver carcinogenesis include the p53/p21 pathway, the p16/cyclin D1/pRB pathway, and the Wnt/wingless signaling pathway (Hui and Makuuchi, 1999; Buendia, 2000) . In addition, multiple growth factors (including TNFa and TGFb), oncogenes (particularly c-myc), and tumor suppressor genes (including IGF2R, SMAD2, SMAD4, DLC-1, and HIC1) have been implicated in hepatocarcinogenesis. The molecular mechanisms involved in hepatocarcinogenesis include promoter hypermethylation, deletions, mutations, and oncogene amplification. Mechanisms specific to hepatitis B virus (HBV)-induced HCC include HBV integration, which leads to the production of novel fusion transcripts, the interruption of genes, genomic instability with secondary insertion and deletion events, and transactivation of cellular genes by HBV proteins, particularly the X and preS gene products. HCV, which is an RNA virus, does not integrate into the host genome, however, the HCV core protein and non-structural proteins NS4B and NS5A have been shown to have potentially tumorigenic effects . Chronic aflatoxin exposure predisposes to mutations in the p53 gene, particularly a G -T transversion at codon 249. In populations exposed to aflatoxin approximately 50% of HCCs contain the G249T transversion (Bressac et al., 1991) .
Alterations of b-catenin, a central molecule in the Wnt signal transduction pathway, occur in approximately 20% of HCCs (Miyoshi et al., 1998; de La Coste et al., 1998; Kondo et al., 1999) . Mutations in exon 3 of CTNNB1, the b-catenin gene, disrupt the serine/ threonine phosphorylation sites normally phosphorylated by glycogen synthase kinase-3b . This interferes with degradation of b-catenin by the ubiquitin-proteosome system, leading to accumulation of free b-catenin in the cytoplasm. Accumulated cytoplasmic bcatenin translocates to the nucleus and binds to members of the T-cell factor/lymphoid enhancer factor (TCF/LEF) protein family; the resulting complexes then activate oncogenic target genes such as c-myc, cyclin D1 and c-jun, which regulate cellular growth and apoptosis (Behrens et al., 1996; Peifer, 1997) . CTNNB1 mutations occur even more frequently in HBs (48 -89%) and are characterized by a high frequency of deletions Koch et al., 1999) . Immunohistochemistry for b-catenin shows overexpression in almost all cases of HB (Koch et al., 1999; Jeng et al., 2000) and in 50 -83% of HCCs (Ihara et al., 1996; Huang et al., 1999) . These data suggest that alterations in the Wnt pathway are involved in the pathogenesis of a significant proportion of both HBs and HCCs.
Since CTNNB1 mutations are only observed in a portion of liver tumors with b-catenin accumulation, it is likely that defects in other components of the Wnt/ b-catenin pathway are tumorigenic in some liver cancers (Kondo et al., 1999) . AXIN1 is an important component of the Wnt pathway which functions by promoting the phosphorylation of b-catenin by GSK3b and the subsequent degradation of b-catenin (Zeng et al., 1997) . AXIN1 has binding domains for APC, GSK-3b, b-catenin, the catalytic subunit of serine/ threonine protein phosphatase PP2A (PP2Ac), the cytoplasmic phosphoprotein dishevelled (Dsh), and AXIN1 itself. AXIN1 appears to function as a scaffold protein on which the complex for phosphorylation of b-catenin by GSK-3b is assembled. The role of AXIN1 in promoting b-catenin degradation suggests that it functions as a tumor suppressor, and recent studies show that it is a mutational target in HCCs (Satoh et al., 2000; Laurent-Puig et al., 2001) , in sporadic medulloblastoma (Dahmen et al., 2001) , and in ovarian endometrioid adenocarcinomas (Wu et al., 2001) . AXIN2, which also functions as a scaffold protein in the Wnt signaling pathway, is mutated in a subset of colorectal cancers (Behrens et al., 1998; Mai et al., 1999; Liu et al., 2000; Dong et al., 2001) . Activation of the Wnt/b-catenin pathway results in up-regulation of AXIN2 expression (Yan et al., 2001) . It has been hypothesized that AXIN1 is a constitutively expressed component of the b-catenin degradation complex that is essential for the maintenance of its basal activity, while AXIN2 is an inducible component that is upregulated in response to increased b-catenin levels and thus serves to limit the duration and intensity of the Wnt/b-catenin signal (Lustig et al., 2001; Yan et al., 2001) . Since AXIN1 and AXIN2 are negative regulators of the Wnt pathway, it is presumed that in cancers in which the Wnt/b-catenin pathway is activated, negative regulation by AXIN1 and AXIN2 is abrogated by alternative overriding pathways.
A number of studies have examined the clinical significance of Wnt/b-catenin pathway mutations in HCC. These studies suggest that HCCs fall into two classes, with either low or high levels of chromosomal instability. HCCs with low level chromosomal instability are also more likely to have disruption of the Wnt signaling pathway, with stabilizing mutations of the bcatenin gene, LOH on chromosome 8p, low-grade histology, and larger tumors. In contrast, HCCs with high level chromosomal instability are more likely to have LOH on multiple chromosomal arms, p53 or AXIN1 mutations, high-grade histology, and a poor long-term prognosis (Laurent-Puig et al., 2001) . HCCs with b-catenin mutations and nuclear b-catenin accumulation may have a better prognosis Mao et al., 2001) . The etiology of HCC may also determine the presence of chromosomal instability and b-catenin mutations in HCC. HBV associated HCCs are more likely to show high-level chromosomal instability with p53 or AXIN1 mutations, while bcatenin mutations are more frequent in HCCs not associated with chronic HBV infection (Huang et al., 1999; Laurent-Puig et al., 2001) .
In this study, we have investigated the mutational status and expression of the CTNNB1, AXIN1, and AXIN2 genes in both HCC and HB and discuss their roles in liver carcinogenesis. We found the expected frequencies of CTNNB1 mutations in HCCs and HBs. AXIN1 mutations were found in approximately 10% of both HCCs and HBs. The AXIN1 mutations were predominantly missense mutations, a difference from the predominance of nonsense or truncation mutations previously described. In addition, AXIN2 mutations were found in two HCCs. Most interestingly, two HCCs had mutations in both the CTNNB1 and AXIN1 genes, and one HCC had mutations in both the CTNNB1 and AXIN2 genes. This phenomenon may represent the activation of Wnt/b-catenin signaling in carcinogenesis through mutational activation of bcatenin and simultaneous abrogation of the negative feedback functions of AXIN1 or AXIN2. Figure 1 ). In all 14 cases the mutation affected the degradation targeting box of b-catenin, which is the region responsible for phosphorylation and ubiquitination of b-catenin. Twelve of the 14 tumors had single point missense mutations, one tumor had a 9 bp insertion, and one tumor had both a missense mutation and an in-frame deletion of 6 bp. In 10 of the 14 HCCs the point mutation altered one of the serine or threonine residues that are targets for phosphorylation by GSK-3b (codons S33, T41, or S45). The other three point mutations and the insertion were clustered around codon S33. Eight of the 14 b-catenin mutations replaced serine 45, which is the most frequently altered amino acid in b-catenin in HCC.
Results

Mutations in
Somatic mutations in the AXIN1 gene were detected in seven (9.6%) of the 73 HCCs. There were five missense mutations, one 1 bp deletion, and one 12 bp insertion (Figure 2a The fifth mutation occurs in an as yet uncharacterized domain between the APC and GSK3b binding domains. To determine whether any of the missense mutations might represent gene polymorphisms, we also screened the AXIN1 gene in 147 normal human controls (data not shown). None of the five 1 bp missense mutations were detected in any of these control samples. These substitutions are therefore unlikely to be polymorphisms. Comparing the four AXIN1 homologs from different organisms that have been sequenced to date, we found that all the substitutions changed a conserved amino acid at each position, except for the G651S mutation in which a serine is present in the mouse and chicken proteins ( Figure 2e ). Two of the tumors with CTNNB1 mutations, HCC-10 and HCC-35, also had AXIN1 mutations. None of the seven HCCs with AXIN1 mutations were from patients with hepatitis B or hepatitis C virus infection. LOH at the AXIN1 locus in association with AXIN1 mutations has previously been reported (Satoh et al., 2000; Laurent-Puig et al., 2001) . This suggests that AXIN1 functions as a tumor suppressor. We analysed LOH at the AXIN1 locus in the tumor samples with AXIN1 mutations (Figure 3) . Four of the five informative samples 34, 36 and 48) , showed LOH at the AXIN1 locus, conforming to the 'two-hit' hypothesis of tumor suppressor inactivation.
Somatic mutations in the AXIN2 gene were found in two HCC tumors, HCC-61 and HCC-78. There was a missense mutation of nucleotide 2064 in HCC-61 and a 12 bp deletion beginning at nucleotide 2102 in HCC78. One tumor, HCC-61, had both a CTNNB1 and an AXIN2 mutation. Both AXIN2 mutations were located in exon 7, which encodes a domain of unknown function. Several frameshift mutations in exon 7 have previously been described in colorectal cancers with defective mismatch repair (Liu et al., 2000) . To determine if the missense mutation in HCC-61 might represent a gene polymorphism, we also screened the AXIN2 gene in 100 normal human controls (data not shown). The missense mutation was not detected in any of these control samples.
b-catenin is expressed in variable patterns in HCCs with Wnt/b-catenin pathway mutations
The functional importance of the AXIN1 and AXIN2 mutations in HCC development was further analysed by immunohistochemical staining of b-catenin in 67 available HCC tissue samples. Seventeen (25%) of the Table 1 show data for tumors with mutations). Almost all of the non-cancerous liver tissues showed a faint b-catenin immunoreactivity on the cell membranes delineating the hepatocytes ( Figure  4a) . Three of the seven HCCs with AXIN1 mutations showed increased membrane and cytoplasmic immunoreactivity for b-catenin (see Figure 4b , sample HCC-48), while one showed increased nuclear, membrane, and cytoplasmic immunoreactivity. In four of the eleven HCCs with b-catenin mutations but no AXIN1 or AXIN2 mutations benign hepatocytes showed no nuclear or cytoplasmic expression of b-catenin ( Figure  4c ), while the malignant cells showed nuclear immunoreactivity (Figure 4d, HCC-83 CTNNB1 deletions are frequent in HBs, AXIN1 mutations only occur in a subset of HBs HB is a pediatric liver tumor with a high frequency of b-catenin mutations (Koch et al., 1999; Jeng et al., 2000) , but the role of AXIN1 or AXIN2 in the development of this tumor has not been investigated. We screened exon 3 of the CTNNB1 gene and identified mutations in 19 (70%) of 27 samples ( Figure  1 , Table 2 ). The CTNNB1 mutations in HBs were significantly different from those in HCCs, as 10 of the 19 tumors had deletions ranging between 38 -657 bp in size. Of the nine tumors with point mutations, five were in one of the serine or threonine residues critical for GSK3 phosphorylation (S33, S37, and T41). The remaining four point mutations in CTNNB1 were in codon 34. One bp substitutions in the AXIN1 gene were identified in two of the 27 tumors (7.4%) ( Figure  2e , Table 2 ). The AXIN1 mutation in one HB (HB-24) was identical to the mutation in one HCC (HCC-35) and located within the PP2Ac domain. The other mutation, in HB-6, was located in the AXIN binding domain. No AXIN2 mutations were detected in the HBs.
Discussion
We have studied the prevalence and mechanisms of Wnt/b-catenin dysregulation by mutations in the mutations showed increased membrane and cytoplasmic or nuclear, membrane, and cytoplasmic immunoreactivity for b-catenin. Of the 14 HCCs, two also had additional mutations in the AXIN1 gene and one had an additional mutation in the AXIN2 gene. Nuclear bcatenin was detected in 25% of 67 HCCs examined. The CTNNB1 mutations identified in HCCs and HBs, the two primary liver tumor types examined, are quite different. Consistent with previous reports, we found that more than half of the CTNNB1 mutations (10 out of 19, 53%) in HB were deletions (ranging from 38 -657 bp), whereas all the CTNNB1 mutations in HCC were missense mutations, minor deletions (6 bp) or small insertions (9 bp) Koch et al., 1999) . This suggests that the mutational mechanisms in HCC and HB are different. Compared to the predominance of missense CTNNB1 point mutations associated with HCC, the disruption of more than one phosphorylation site due to deletion of the entire, or a large portion of, exon 3 in the CTNNB1 gene in HBs may have a more severe impact on normal development of the liver and thus result in early onset pediatric liver cancer.
AXIN1 mutations or deletions have recently been reported in two separated studies in five of 100 (5%) primary HCC tumors and three of six (50%) HCC cell lines (Satoh et al., 2000) and in 12 of 137 (8.8%) primary HCCs (Laurent-Puig et al., 2001). We found a similar frequency of AXIN1 mutations in the primary HCCs (9.6%). The pooled data from all three studies shows mutations in 24 of 310 (7.7%) HCCs. The AXIN1 mutations identified in the previous reports include truncation mutations due to either small deletions or nonsense mutations. We detected five missense mutations, one truncation mutation due to a 1 bp deletion, and one in-frame 12 bp insertion. We did not detect any nonsense mutation of this gene in our HCC samples. All but one of the point mutations were located in known functional domains of AXIN1. The different spectrum of AXIN1 mutations identified in our study could be due to differences in the populations examined or may reflect the small numbers of mutations analysed so far. LOH at the AXIN1 locus was observed in three of five HCCs with AXIN1 mutations by Satoh et al. (2000) and in 10 of 12 HCCs with AXIN1 mutations by Laurent-Puig et al. This suggests that AXIN1 functions as a tumor suppressor (Satoh et al., 2000) . In support of this hypothesis, expression of wild type AXIN1 in HCC or colorectal cancer cells with APC, CTNNB1 or AXIN1 mutations led to the induction of apoptosis (Satoh et al., 2000) . Our results showing LOH at the AXIN1 locus in four of the five informative samples analysed are in agreement with the findings of the previous studies. A strong association between HBV infection and the presence of AXIN1 mutations in HCC has been reported (Laurent-Puig et al., 2001) . This association was not confirmed in our study, perhaps because of the small number of patients with chronic HBV infection in our sample. Analysis of the hepatitis virus infection status of our tumor samples showed that none of the seven HCCs with AXIN1 mutations were from patients with hepatitis B or hepatitis C virus infection. It will be interesting and important to investigate further the correlation between hepatitis infection status and the AXIN1, AXIN2 and b-catenin mutation in liver cancer K Taniguchi et al spectrum of AXIN1 mutations in HCC. AXIN1 mutations were found in two of the 27 HBs examined. The mutation in one of the HBs was identical to that found in one of the HCCs. AXIN2 mutations were found in two of the 73 HCCs, a relatively small proportion, and in none of the HBs. In two HCCs, CTNNB1 mutations were found to co-exist with AXIN1 mutations. In a third tumor, there was both a CTNNB1 and an AXIN2 mutation. The presence of mutations in both genes suggests that the tumorigenic functions of mutations in the two genes are not identical and hints at complexities in Wnt signal transduction that are only now being appreciated. In particular, recent reports have shown that AXIN1 is constitutively expressed in cells, whereas Wnt/b-catenin activation leads to up-regulation of AXIN2 expression. Recently published studies have shown that AXIN2 is a transcriptional target of the TCF/LEF transcription factor complex downstream of activated b-catenin (Jho et al., 2002; Lustig et al., 2002) . Since AXIN2 promotes b-catenin degradation, increased AXIN2 expression functions in a negative feedback loop to counteract the tumorigenic effects of b-catenin mutations. This may explain the presence of tumors with mutations in both the CTNNB1 and AXIN1 or AXIN2 genes, with inactivation of the AXIN1 or AXIN2 genes contributing to the activation of the Wnt signaling pathway. Since both AXIN1 and AXIN2 are negative regulators of the Wnt signaling pathway, it has been hypothesized that activation of the Wnt/b-catenin pathway during carcinogenesis is associated with the induction of pathways that abrogate or annul the function of AXIN1 and/or AXIN2. This study provides evidence for this hypothesis in three HCCs with combined mutations in CTNNB1 and AXIN1 or CTNNB1 and AXIN2. On the other hand, most HCCs with AXIN1 or AXIN2 mutations did not have CTNNB1 mutations and the AXIN1 or AXIN2 mutations, perhaps in combination with other as yet uncharacterized Wnt/b-catenin pathway alterations, were presumably able to contribute to hepatocarcinogenesis in those instances.
Tumors with mutations in CTNNB1 or both CTNNB1 and AXIN1 did not show a consistent increase in nuclear b-catenin accumulation when compared to adjacent benign liver tissue. Both HCCs with AXIN2 mutations, including one with mutations in both CTNNB1 and AXIN2, showed increased nuclear immunostaining for b-catenin. There has been a limited number of tumors with AXIN1 mutations identified to date, and it is not yet known how well AXIN1 mutation correlates with aberrant localization of b-catenin. Indeed, tumors with documented CTNNB1 mutations do not always show nuclear or cytoplasmic accumulation of b-catenin, a phenomenon also confirmed in this study. Although AXIN2 mutations have not previously been reported in HCCs, previous reports showed increased nuclear b-catenin staining in 10 of 11 colorectal cancers with AXIN2 mutations (Liu et al., 2000) and absent/weak cytoplasmic and membrane staining in a single ovarian endometrioid adenocarcinoma (Wu et al., 2001) .
Analysis of the clinicopathological correlation of mutations in the CTNNB1, AXIN1, and/or AXIN2 genes with histopathologic grade of HCCs confirmed the finding in some, but not all, studies of significantly lower histologic grade in HCCs with CTNNB1 mutations. Sixteen (80%) of the 20 HCCs with CTNNB1, AXIN1, and/or AXIN2 mutations were grade 1 or 2, compared to 28 (53%) of 53 HCCs without mutations (data not shown) (P=0.06, Fisher's exact test). There is therefore a strong trend towards lower histologic grade in the combined group of HCCs with CTNNB1, AXIN1, and/or AXIN2 mutations. Analysis of the results for HCCs with CTNNB1 mutations, excluding HCCs with only AXIN1 or AXIN2 mutations, showed a significant association of CTNNB1 mutations with lower histologic grade; 12 (86%) of the 14 HCCs with CTNNB1 mutations were grade 1 or 2, compared to 32 (54%) of 59 HCCs without CTNNB1 mutations (P=0.04, Fisher's exact test). As lower histologic grades have been reproducibly shown to correlate with better patient outcomes, this finding is consistent with previous reports demonstrating increased survival in HCC patients with CTNNB1 mutations Mao et al., 2001) . It has been suggested that HCCs with AXIN1 mutations have a different phenotype and are more likely to have high levels of chromosomal instability, p53 mutations, and high-grade, less well differentiated histology. We did not find enough mutations in this study to reliably detect a significant difference in histologic grade between HCCs with CTNNB1 mutations and HCCs with AXIN1 mutations.
Overall, the frequency of alterations in the CTNNB1, AXIN1, and/or AXIN2 genes in HCC (20 of 73 cases, 27%) is significantly lower than the frequency of alterations in HB (21 of 27 cases, 78%). Since the Wnt signaling pathway has important functions in embryonic development, it is perhaps not surprising that this pathway appears to have a more important role in tumorigenesis of the pediatric form of liver cancer, HB, than in the adult form, HCC. Neither of the HBs with AXIN1 mutations had a mutation in CTNNB1 exon 3 and both mutations also occurred in known functional domains of the AXIN1 gene. Unfortunately, paraffin blocks were not available for immunohistochemistry studies on the HBs. However, since the two AXIN1 mutations in HBs are located in functional domains of AXIN1 (Figure 1e ) and since it has been previously reported that almost all HBs show positive b-catenin staining (Koch et al., 1999; , it is probably that the two tumors with AXIN1 mutations would also show higher intracellular levels of b-catenin. This finding extends and confirms the central role of the Wnt signaling pathway in the development of HB. Analysis of AXIN1 in a larger set of tumors is needed to delineate the relative importance of this gene in HB development. No AXIN2 mutations were identified in the 27 HBs examined.
In summary, our findings provide additional evidence for diverse mechanisms of b-catenin dysregulation in both HCC and HB, including mutation of b-catenin and mutational inactivation of AXIN1 and AXIN2. The pattern of b-catenin mutations is strikingly different in HCCs compared to HBs. This suggests the presence of different mutagenic mechanisms in the two tumor types and raises intriguing questions about the underlying pathogenetic mechanisms involved in development of these two tumors. We have demonstrated that AXIN1 mutations in HB and AXIN2 mutations in HCC may contribute to bcatenin dysregulation in a subset of these tumor types. The identification of coexisting CTNNB1 and AXIN1 or AXIN2 mutations confirms the complementary function of these molecules in the function of the Wnt/b-catenin signaling pathway, and suggests the likely presence of additional co-mutations of CTNNB1 and other Wnt/b-catenin pathway genes. The presence of Wnt/b-catenin pathway mutations was associated with lower histological grade HCCs and presumably with better prognosis. Further studies are underway to investigate the specific tumorigenic effects of the novel AXIN1 and AXIN2 mutations reported in this study.
Materials and methods
Tumor samples
HCC samples and matched adjacent benign liver samples were collected during surgical resections at the Mayo Clinic between 1991 and 1999. Fibrolamellar hepatocellular carcinomas and mixed cholangio-hepatocellular carcinomas were excluded from the series. There were 41 males and 32 females. Eleven patients had HBV infection as confirmed by serological testing or PCR testing of benign or tumor DNA. For seven patients HBV status could not be determined unequivocally. The remaining 55 patients were HBV negative. Seven patients were HCV positive, 10 had unknown HCV status, and 56 were HCV negative. Of the hepatitis positive patients, two were positive for both HBV and HCV. Fresh tumor samples and samples of adjacent benign liver tissue were collected at the time of surgery and frozen at 7808C. Sections from each specimen were examined by a pathologist and graded histologically (grades 1 -4). HB samples were provided by the Cooperative Human Tissue Network (CHTN, Columbus, OH, USA).
HCC cell lines
The following HCC cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured as recommended by ATCC; HepG2, Hep3B, Huh-7, PLC/PRF/5, SK-Hep-1, SNU182, SNU387, SNU398, SNU423, SNU449, and SNU475.
DNA preparation
Tumor tissues were embedded in OCT medium and sectioned on a cryostat. Representative sections were stained and examined periodically to confirm the tumor histology. Each tumor sample contained at least 70% tumor cells. High molecular weight genomic DNA was extracted using the Easy-DNATM kit (Invitrogen, Carlsbad, CA, USA) following the manufacturer's instructions.
PCR
The two pairs of CTNNB1 exon 3 primers P3-4 and P5-6 used in this study have been reported previously (MirabelliPrimdahl et al., 1999) . The 13 pairs of AXIN1 primers used in this study are as follows: exon 1A, 5'-TGGTCGTGTTTC-ATGGACCC-3' and 5'-AATGCAGTGACTCAGCCCACT-3'; exon 1B, 5'-GGATCTGGACCTGGGGTATG-3' and 5'-ATAGTGGCCTGGATTTCGGT-3'; exon 1C, 5'-ATCATG-AAGCAGCTGATCG-3' and 5'-GAGGTGAGTACAGAA-AGTGGAC-3'; exon 2, 5'-CTGTTGGCAGGCTGTCACT-3' and 5'-GTCCGTGAGGGACTGGGTA-3'; exon 3, 5'-CTG-GCCCTCCTGCTCCTCT-3' and 5'-AGGACGATGGGCT-GAGGAC-3'; exon 4, 5'-TTTAGCCTGTGACCTTTC AAC-3' and 5'-ATCCCGGCGGCAAGAA-3'; exon 5A, 5'-AGC-TGGTGCTGAGAGGTGATG-3' and 5'-CCCTGACTTGG-GTACGTGCTT-3'; exon 5B, 5'-TGGGCACGTGGCCAA-GAT-3' and 5'-AAGCCCCCTCCTCACTGACAG-3'; exon 6, 5'-CACCGGAGGCCAGGGCGACT-3' and 5'-TGGCA-AAGCAGGCCCCACGA-3'; exon 7, 5'-CCAGGGTGTCG-GCCACAGTC-3' and 5'-CCCCAGGAGTGGTGCTGTG-GT-3'; exon 8, 5'-GCGCAGCAGCATTGGTCGAG-3' and 5'-GGGCAGGACCGGGAGGACC-3'; exon 9, 5'-AGTC-CAAAACCAGGTACCAC-3' and 5'-AAACCCTCTTTTT-CATACCG-3'; exon 10, 5'-CACGCCGTCCCCTGCCAC-3' and 5'-GACACCCGTGCCCGCCAA-3'. AXIN2 primers were as previously described (Liu et al., 2000) . Samples used for mutation screening and sequencing were amplified in 25 ml reaction volumes containing 50 ng of genomic DNA, 25 pmoles each of sense and antisense primers, dNTPs (Perkin-Elmer, Foster City, CA, USA), 0.2 ml of Taq polymerase (AmpliTaq Gold, Perkin-Elmer), 16 buffer provided by the manufacturer, and 2.0 mM of MgCl 2 . PCR amplification was for 35 cycles using the following profile: 948C for 30 s, the optimized annealing temperature for 45 s, and 728C for 45 s (60 s for P5-6). The enzyme was initially activated by denaturation at 958C for 9 min, and final extension was performed at 728C for 10 min. The annealing temperatures for various primer sets were 588C for AXIN1 exons 1A, 1B, 1C, 2, 3, 4 and 9; 638C for exons 5A, 6, 7, 8 and 10; 628C for exon 5B, 608C for P3-4 and 558C for P5-6. P5-6 products were subjected to 1% agarose gel electrophoresis. The band was cut out, purified and subjected to denaturing HPLC analysis.
Denaturing HPLC analysis and DNA sequencing
The procedure used for DHPLC has been previously described (Liu et al., 1998) . PCR products with an abnormal DHPLC elution profile or size were sequenced directly as described (Liu et al., 1998) . For samples in which an insertion or deletion mutation was suspected, the PCR product was cloned into pGEM-T vector (Promega, Madison, WI, USA) and several clones were isolated and sequenced by the Mayo Clinic DNA sequencing facility using T7 or SP6 sequencing primers. All sequence alterations were confirmed by bidirectional sequencing of PCR products generated by at least two independent reactions.
Loss of heterozygosity (LOH) analysis
Microsatellite marker D16S521 at the AXIN1 locus was examined for LOH (Satoh et al., 2000) . The PCR products were fractionated under non-denaturing conditions on the WAVE System TM (Transgenomic, Omaha, NE, USA). The gradient of buffer B was 49 -57% from 1 -7 min. The column temperature was 508C and the flow rate was 0.9 ml/min. AXIN1, AXIN2 and b-catenin mutation in liver cancer K Taniguchi et al
Immunohistochemical analysis of b-catenin
The surgically resected HCC specimens were fixed in 10% buffered formalin and embedded in paraffin. Five micron sections were stained with hematoxylin-eosin and examined histologically to confirm that the sections show adjacent areas of benign and tumor tissue. After deparaffinization and rehydration of the samples, heat-induced epitope retrieval was performed using 1 mM EDTA, pH 8.0, and a commercial vegetable steamer. Staining was performed using the DAKO autostainer immunostaining system (DAKO, Carpinteria, CA, USA) with b-catenin E5 mouse monoclonal antibody (SC-7963, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) as primary antibody at a 1 : 500 dilution and the DAKO EnVision+ System Peroxidase kit (K4005) following the manufacturer's recommendations. Grade 2 colon adenocarcinoma sections were used as positive controls. Internal positive controls were provided by the bile ducts in the liver tissue, which showed a strong immunoreactivity in all samples. Another set of identical slides was used following the same protocol, but omitting the primary antibody, to serve as a negative control.
